Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Erbitux cetuximab: Phase III data

In an international Phase III study in 424 patients, 69% and 56% of patients receiving Erbitux plus

Read the full 176 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE